Voyager Therapeutics, Inc. (VYGR) NASDAQ
3.66
-0.135(-3.56%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Voyager Therapeutics, Inc.
Address
75 Sidney Street
Lexington, MA 02139
United States of America (the)
Phone
857 259 5340
Sector
Healthcare
Industry
Biotechnology
Employees
172
First IPO Date
November 11, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Alfred W. Sandrock Jr. | President, Chief Executive Officer & Director | 1.05M | 1958 |
| Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer | 0 | 1977 |
| Nathan D. Jorgensen | Chief Financial Officer | 577,748 | 1977 |
| Robin Swartz | Principal Financial Officer, Treasurer, Chief Business Officer & COO | 738,950 | 1971 |
| Mark A. Kay | Founder | 0 | 1959 |
| Krystof Bankiewicz | Founder | 0 | N/A |
| Mathieu Nonnenmacher | Vice President of Gene Therapy | 0 | N/A |
| Mihalis Kariolis | Vice President of Non-Viral Therapeutics | 0 | N/A |
| Gregory Shiferman | Senior VP, General Counsel & Secretary | 0 | 1985 |
| Todd Carter | Chief Scientific Officer | 0 | 1970 |
| Amy Quinlan | Principal Accounting Officer | 0 | 1975 |
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
